Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock
10 November 2021 - 8:30AM
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the
“Company”), a neurotech company focused on neurological wellness,
today announced that it has commenced a proposed underwritten
registered public offering of shares of its common stock.
All of the shares of common stock to be sold in the proposed
offering will be sold by the Company. In addition, the Company
intends to grant the underwriter a 45-day option to purchase up to
an additional 15% of the shares of its common stock sold in the
offering. The proposed offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
The Company intends to use the net proceeds from this proposed
offering for funding operations, working capital and other general
corporate purposes.
Ladenburg Thalmann & Co. Inc. is acting as the sole
book-running manager for the offering.
The proposed offering is being made pursuant to a shelf
registration statement on Form S-3 (File No. 333-236101) that was
declared effective by the U.S. Securities and Exchange Commission
(“SEC”), on February 6, 2020. A preliminary prospectus supplement
and accompanying prospectus relating to the proposed offering will
be filed with the SEC and will be available on the SEC’s website at
www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc.,
Prospectus Department, 640 Fifth Avenue, 4th floor, New York, NY
10019 by email at prospectus@ladenburg.com.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. Any offer,
if at all, will be made only by means of a prospectus, including a
prospectus supplement, forming a part of the effective registration
statement.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s purpose is
to develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first commercial product is the Portable Neuromodulation
Stimulator (PoNSTM). For more information,
visit www.heliusmedical.com.
Forward Looking Statements
Certain statements in this news release are not based on
historical facts and constitute forward-looking statements or
forward-looking information within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. All statements other than statements of historical fact
included in this news release are forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
often identified by terms such as “believe,” “continue,” “intends
to,” “expect,” “will,” “goal,” “aim to” and similar expressions.
Such forward-looking statements include, among others, statements
regarding the Company’s anticipated closing of the public offering
and anticipated use of proceeds therefrom.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those expressed or implied by such statements.
Important factors that could cause actual results to differ
materially from the Company’s expectations include risks and
uncertainties related to market and other conditions, the
satisfaction of customary closing conditions related to the
proposed public offering, the impact of general economic, industry
or political conditions in the United States or internationally and
other risks described under the heading “Risk Factors” in our
filings with the Securities and Exchange Commission and the
Canadian securities regulators, which can be obtained from either
at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any
forward-looking statement. The forward-looking statements contained
in this news release are made as of the date of this news release
and the Company assumes no obligation to update any forward-looking
statement or to update the reasons why actual results could differ
from such statements except to the extent required by law.
Investor Relations Contact:
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024